☆ 4.3 Letter

MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia

LEUKEMIA & LYMPHOMA (2013)

期刊

LEUKEMIA & LYMPHOMA

卷 54, 期 5, 页码 1087-1090

出版社

INFORMA HEALTHCARE

DOI: 10.3109/10428194.2012.723706

关键词

-

类别

Oncology Hematology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Multidisciplinary Sciences

Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation

Zachary A. Hing, Janek S. Walker, Ethan C. Whipp, Lindsey Brinton, Matthew Cannon, Pu Zhang, Steven Sher, Casey B. Cempre, Fiona Brown, Porsha L. Smith, Claudio Agostinelli, Stefano A. Pileri, Jordan N. Skinner, Katie Williams, Hannah Phillips, Jami Shaffer, Larry P. Beaver, Alexander Pan, Kyle Shin, Charles T. Gregory, Gulcin H. Ozer, Selen A. Yilmaz, Bonnie K. Harrington, Amy M. Lehman, Lianbo Yu, Vincenzo Coppola, Pearlly Yan, Peggy Scherle, Min Wang, Philip Pitis, Chaoyi Xu, Kris Vaddi, Selina Chen-Kiang, Jennifer Woyach, James S. Blachly, Lapo Alinari, Yiping Yang, John C. Byrd, Robert A. Baiocchi, Bradley W. Blaser, Rosa Lapalombella

Summary: PRMT5 plays an important role in the progression of CLL to Richter transformation, and the PRMT5 inhibitor PRT382 shows potential therapeutic value.

NATURE COMMUNICATIONS (2023)

添加到收藏夹

Review Oncology

Double-Hit Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes

Florence Nguyen-Khac

Summary: Although the 17p deletion is rare in treatment-naive CLL, its frequency is higher in refractory/relapsed CLL, especially in patients undergoing chemotherapy. TP53 disruption is the strongest prognostic factor for chemotherapy resistance, and the use of Bruton tyrosine kinase inhibitors and BCL2 inhibitors is recommended. Rare cases of CLL may also have translocation or gain of the MYC oncogene, and double-hit CLL (with del(17p) and MYC gain) has a very poor prognosis. The prognostic impact of TP53 disruption with MYC aberrations in patients receiving targeted therapies needs to be evaluated.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Hematology

Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia

Delphine Tardivon, Mateusz Antoszewski, Nadine Zangger, Marianne Nkosi, Jessica Sordet-Dessimoz, Rudi Hendriks, Ute Koch, Freddy Radtke

Summary: NOTCH1 gain-of-function mutations are common in B-cell chronic lymphocytic leukemia, and play a role in disease progression and chemotherapy resistance. In an in vivo mouse model of CLL, activation of Notch signaling facilitated disease initiation and promoted CLL cell proliferation and disease progression, while inhibition of Notch signaling delayed disease induction.

BLOOD (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia

Wei-Yu Lin, Sarah E. Fordham, Nicola Sunter, Claire Elstob, Thahira Rahman, Elaine Willmore, Colin Shepherd, Gordon Strathdee, Tryfonia Mainou-Fowler, Rachel Piddock, Hannah Mearns, Timothy Barrow, Richard S. Houlston, Helen Marr, Jonathan Wallis, Geoffrey Summerfield, Scott Marshall, Andrew Pettitt, Christopher Pepper, Christopher Fegan, Francesco Forconi, Martin J. S. Dyer, Sandrine Jayne, April Sellors, Anna Schuh, Pauline Robbe, David Oscier, James Bailey, Syed Rais, Alison Bentley, Lynn Cawkwell, Paul Evans, Peter Hillmen, Guy Pratt, David J. Allsup, James M. Allan

Summary: Prognostication in CLL patients is challenging due to its heterogeneous clinical course. This study identifies two genomic locations associated with disease progression, highlighting the impact of constitutional genetic variation on CLL prognosis. Additionally, functional genes implicated in modulating key pathways in CLL pathogenesis are identified.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, General & Internal

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fuerstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindstrom, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Bjoern Schoettker, Thomas Noesslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jaeger, Maria B. L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brueggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek

Summary: In fit patients with CLL, venetoclax-obinutuzumab, with or without ibrutinib, showed superior results compared to chemoimmunotherapy as a first-line treatment, with higher rates of undetectable minimal residual disease and progression-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Nucleosome repositioning in chronic lymphocytic leukemia

Kristan V. Piroeva, Charlotte Mcdonald, Charalampos Xanthopoulos, Chelsea Fox, Christopher T. Clarkson, Jan-Philipp Mallm, Yevhen Vainshtein, Luminita Ruje, Lara C. Klett, Stephan Stilgenbauer, Daniel Mertens, Efterpi Kostareli, Karsten Rippe, Vladimir B. Teif

Summary: This study compared the nucleosome positions in chronic lymphocytic leukemia (CLL) patients and healthy individuals, and found significant changes in nucleosome positioning in CLL. The spacing between nucleosomes was shortened, and changes in nucleosome occupancy were linked to chromatin remodeling and reduced DNA methylation. Nucleosome positioning can be used to classify CLL subtypes and monitor disease progression.

GENOME RESEARCH (2023)

添加到收藏夹

Article Cell Biology

Normal and Neoplastic Growth Suppression by the Extended Myc Network

Edward V. Prochownik, Huabo Wang

Summary: MYC is one of the earliest discovered cellular oncogenes and encodes a bHLH-ZIP transcription factor with both activating and suppressing functions on genes related to proliferation, energy production, and metabolism. The Myc Network includes Myc, Max, and six Mxd proteins, while the Mlx Network bears parallels with it. Both networks regulate target genes with some shared between them.

CELLS (2022)

添加到收藏夹

Article Oncology

Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis of MYC Aberrations

Eva Ondrouskova, Michaela Bohunova, Kristyna Zavacka, Patrik Cech, Petra Smuharova, Miroslav Boudny, Martina Orsulova, Anna Panovska, Lenka Radova, Michael Doubek, Karla Plevova, Marie Jarosova

Summary: Chronic lymphocytic leukemia (CLL) patients with the chromosomal abnormality +8q are associated with adverse clinical outcomes and shorter overall survival. This study used FISH and M-FISH analysis to determine the frequency and specific region of +8q amplification. These findings contribute to a better understanding of the molecular characteristics and prognostic factors of CLL.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability

Kristyna Zavacka, Karla Plevova

Summary: Chromothripsis, a mechanism of massive chromosome shattering and reassembly, has been observed in various cancer types, particularly in chronic lymphocytic leukemia (CLL), where it has significant impact on the disease pathology. Recent studies suggest that chromothripsis may be more common than initially thought, especially in CLL cases with adverse clinical outcomes.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Exploring the pathways to chronic lymphocytic leukemia

Freda K. Stevenson, Francesco Forconi, Thomas J. Kipps

Summary: Research into chronic lymphocytic leukemia has led to significant improvements in the assessment and treatment of patients, with designer drugs now successfully targeting tumor cells based on their biology. Classifying CLL into unmutated (U) and mutated (M) diseases based on the mutational status of IGHV sequences reveals distinct origins, biology, and clinical behaviors for each. Despite advances, challenges such as cell-escape strategies and immunosuppression remain, necessitating continued research into CLL biology.

BLOOD (2021)

添加到收藏夹

Article Hematology

The protein landscape of chronic lymphocytic leukemia

Fabienne Meier-Abt, Junyan Lu, Ester Cannizzaro, Marcel F. Pohly, Sandra Kummer, Sibylle Pfammatter, Laura Kunz, Ben C. Collins, Ferran Nadeu, Kwang Seok Lee, Peng Xue, Myriam Gwerder, Michael Roiss, Jennifer Huellein, Sebastian Scheinost, Sascha Dietrich, Elias Campo, Wolfgang Huber, Ruedi Aebersold, Thorsten Zenz

Summary: This study uncovered mutations affecting protein expression in CLL and identified signaling pathways associated with trisomy 12. STAT2 protein expression was linked to specific drug responses, providing a protein expression reference map for CLL.

BLOOD (2021)

添加到收藏夹

Review Oncology

Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective

Marwan Kwok, Catherine J. Wu

Summary: In recent years, there have been significant advancements in our understanding of clonal evolution in high-risk CLL, highlighting recent discoveries, paradigm shifts, and unresolved questions. These advancements have been facilitated by a maturing definition of high-risk CLL and an increasing sophistication of next-generation sequencing technology.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Telomere Dysfunction in Chronic Lymphocytic Leukemia

Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer

Summary: Telomeres play a crucial role in chronic lymphocytic leukemia (CLL), with their dysfunction shaping the disease progression. Members of the shelterin complex and TERT activation are closely associated with CLL cell survival and proliferation.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

Diagnosis and Treatment of Chronic Lymphocytic Leukemia A Review

Mazyar Shadman

Summary: Chronic lymphocytic leukemia is an immunocompromised blood cancer that can be treated with targeted agents like BTK inhibitors or BCL2 inhibitors, but currently there is no cure for the disease.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

添加到收藏夹

Article Oncology

Inactivated STAT5 pathway underlies a novel inhibitory role of EBF1 in chronic lymphocytic leukemia

Chong Wang, Lingling Li, Mengya Li, Xiaohui Shen, Yanfang Liu, Shujuan Wang

Summary: This study revealed that EBF1 is downregulated in CLL patients, but overexpression of EBF1 can inhibit cellular functions of CD20(+) B lymphocytes by disrupting the STATS pathway and promoting apoptosis. Additionally, EBF1 demonstrated anti-tumor effects in nude mice.

EXPERIMENTAL CELL RESEARCH (2021)

添加到收藏夹

Letter Hematology

In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103

Filippo Spriano, Chiara Tarantelli, Alberto J. Arribas, Eugenio Gaudio, Luciano Cascione, Luca Aresu, Andrea Rinaldi, Emanuele Zucca, Davide Rossi, Anastasios Stathis, Maximilien Murone, Freddy Radtke, Rajwinder Lehal, Francesco Bertoni

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Article Hematology

The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy

Francesca Arruga, Marta Rubin, Despoina Papazoglou, Andrea Iannello, Nikolaos Ioannou, Riccardo Moia, Davide Rossi, Gianluca Gaidano, Marta Coscia, Luca Laurenti, Giovanni D'Arena, John N. Allan, Richard R. Furman, Tiziana Vaisitti, Alan G. Ramsay, Silvia Deaglio

Summary: This study investigated the expression of TIGIT and CD226 in patients with CLL and found that patients with a higher TIGIT/CD226 ratio have a slower disease progression, while those with higher CD226 expression have a faster progression. Furthermore, TIGIT expression is negatively correlated with BCR signaling capacity, and it is downregulated in CLL cells treated with ibrutinib. These findings uncover novel molecular mechanisms regulating CLL cell functions.

HAEMATOLOGICA (2023)

添加到收藏夹

Review Oncology

Richter transformation in Chronic Lymphocytic Leukemia

Idanna Innocenti, Giulia Benintende, Annamaria Tomasso, Alberto Fresa, Francesco Autore, Luigi Maria Larocca, Luca Laurenti

Summary: Chronic lymphocytic leukemia can transform into an aggressive lymphoma called Richter syndrome. Immunogenotypic features of Richter syndrome include unmutated IgHV status, deletion of chromosome 17p or 11q, activation of oncogenes, and inactivation of onco-suppressors. The prognosis for patients with Richter syndrome is very poor, and current treatment options are limited. Understanding the biology of this condition is crucial for personalized treatment and improving survival.

HEMATOLOGICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study

Vincenzo Ficarra, Marta Rossanese, Manuel Gilante, Mauro Foti, Luciano Macchione, Giuseppe Mucciardi, Maurizio Martini, Gianluca Giannarini

Summary: Retzius-sparing robot-assisted radical prostatectomy (RARP) shows better functional outcomes and comparable oncological safety compared to the standard approach.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

添加到收藏夹

Review Oncology

Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy

Abdurraouf Mokhtar Mahmoud, Gianluca Gaidano, Samir Mouhssine

Summary: Richter Syndrome is the development of aggressive lymphoma in patients with chronic lymphocytic leukemia. It occurs in 1-10% of CLL patients and is refractory to conventional therapies. Recent research has shown that this syndrome is partly related to immune system dysfunction, suggesting that immunotherapy may be an effective treatment.

CANCERS (2023)

添加到收藏夹

Article Oncology

P53 expression in cytology samples may represent a marker of early-stage cancer

Federica Policardo, Pietro Tralongo, Damiano Arciuolo, Vincenzo Fiorentino, Lina Cardasciani, Francesco Pierconti, Angela Carlino, Mariangela Curatolo, Alfredo Pontecorvi, Guido Fadda, Carmela De Crea, Celestino Pio Lombardi, Marco Raffaelli, Luigi Maria Larocca, Liron Pantanowitz, Esther Diana Rossi

Summary: The TP53 gene plays a crucial role in cell proliferation control and signaling regulation. TP53 mutation is associated with the malignant transformation of thyroid cells and tumor progression. This study found that the expression of p53 in cytology samples was correlated with malignant pathology diagnosis. p53 may be a useful marker for distinguishing thyroid follicular lesions.

CANCER CYTOPATHOLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach

Quintino G. D'Alessandris, Maurizio Martini, Tonia Cenci, Rina DI Bonaventura, Liverana Lauretti, Vittorio Stumpo, Alessandro Olivi, Luigi M. Larocca, Roberto Pallini, Nicola Montano

Summary: This study reports the results of a precision medicine protocol for recurrent glioblastoma, which showed improved outcomes compared to studies without molecular selection. Different treatment approaches were administered based on the molecular pattern of the patients.

JOURNAL OF NEUROSURGICAL SCIENCES (2023)

添加到收藏夹

Article Oncology

Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL

Dean Bryant, Lindsay Smith, Karly Rai Rogers-Broadway, Laura Karydis, Jeongmin Woo, Matthew D. Blunt, Francesco Forconi, Freda K. Stevenson, Christopher Goodnow, Amanda Russell, Peter Humburg, Graham Packham, Andrew J. Steele, Jonathan C. Strefford

Summary: Chronic lymphocytic leukaemia (CLL) cells can express unmutated (U-CLL) or mutated (M-CLL) immunoglobulin heavy chain (IGHV) genes, with differences in clinical behaviors, B cell receptor (BCR) signaling capacity, and transcriptional profiles. Through mRNA/miRNA sequencing of 38 CLL cases, researchers identified differentially expressed mRNAs and miRNAs between U-CLL and M-CLL, as well as potential regulatory roles of the 14q32 miRNA locus in CLL-related gene regulation and BCR signaling.

LEUKEMIA (2023)

添加到收藏夹

Article Medicine, General & Internal

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fuerstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindstrom, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Bjoern Schoettker, Thomas Noesslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jaeger, Maria B. L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brueggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek

Summary: In fit patients with CLL, venetoclax-obinutuzumab, with or without ibrutinib, showed superior results compared to chemoimmunotherapy as a first-line treatment, with higher rates of undetectable minimal residual disease and progression-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Letter Medicine, General & Internal

BCL2 Inhibition in Refractory Hairy-Cell Leukemia

Francesco Forconi, Margaret Ashton-Key, Nicola Meakin

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Review Oncology

Autophagic-Related Proteins in Brain Gliomas: Role, Mechanisms, and Targeting Agents

Cristina Pizzimenti, Vincenzo Fiorentino, Mariausilia Franchina, Maurizio Martini, Giuseppe Giuffre, Maria Lentini, Nicola Silvestris, Martina Di Pietro, Guido Fadda, Giovanni Tuccari, Antonio Ieni

Summary: The present review discusses the cellular process of autophagy, which plays a dual role as both a tumour promoter and a tumour suppressor. Molecular mechanisms and regulatory pathways of autophagy are analyzed, with a particular focus on human astrocytic neoplasms. Additionally, the relationships between autophagy, the tumour immune microenvironment, and glioma stem cells are explored. The development of autophagy-targeting drugs is also discussed, which could potentially improve the treatment of therapy-resistant patients.

CANCERS (2023)

添加到收藏夹

Review Health Care Sciences & Services

Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma

Ilaria Girolami, Stefano Marletta, Vincenzo Fiorentino, Simonetta Battocchio, Bruna Cerbelli, Barbara Fiamengo, Clara Gerosa, Andrea Gianatti, Luca Morelli, Giulio Riva, Maria Giovanna Zagami, Nicola Fusco, Enrico Munari, Vincenzo L'Imperio, Fabio Pagni, Patrizia Morbini, Maurizio Martini, Albino Eccher

Summary: A systematic review of 15 studies comparing PD-L1 expression before and after conventional therapy in head and neck squamous cell cancer revealed heterogeneous results. However, a quantitative analysis showed a trend towards an increase in PD-L1 expression in tumor cells after platinum-based therapy. Further studies are needed for more robust data.

JOURNAL OF PERSONALIZED MEDICINE (2023)

添加到收藏夹

Article Health Care Sciences & Services

Post-Surgical Indications to Radioiodine Treatment and Potential Risk Factors for Post-Treatment Recurrence in Patients with Intermediate-Risk Differentiated Thyroid Carcinoma

Mattia Rossi, Chiara Mele, Ruth Rossetto Giaccherino, Letizia Meomartino, Denise Brero, Giulia Marsan, Gianluca Aimaretti, Ezio Ghigo, Loredana Pagano

Summary: This study investigated the potential risk factors for radioiodine treatment and post-treatment recurrence in patients with intermediate-risk differentiated thyroid cancer. The study found that extra-thyroid micro-extension, pT3 staging, and the presence of large, multiple or clinically evident lymph node metastases were the main indicators for referring patients to radioiodine treatment. Early recurrence was identified as the most relevant factor for planning further surveillance.

JOURNAL OF PERSONALIZED MEDICINE (2023)

添加到收藏夹

Article Oncology

XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression

Jack G. Fisher, Amber D. P. Doyle, Lara V. Graham, Shreyanshi Sonar, Ben Sale, Isla Henderson, Luis Del Rio, Peter W. M. Johnson, Yosef Landesman, Mark S. Cragg, Francesco Forconi, Christopher J. Walker, Salim. I. Khakoo, Matthew D. Blunt

Summary: The XPO1 inhibitor selinexor is being investigated in combination with the BTK inhibitor ibrutinib for CLL and non-Hodgkin lymphoma. Selinexor induces apoptosis of tumor cells and modulates NK cell and T cell cytotoxicity against lymphoma cells.

LEUKEMIA (2023)

添加到收藏夹

Article Cell Biology

High BECN1 Expression Negatively Correlates with BCL2 Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy

Amreen Salwa, Alessandra Ferraresi, Eleonora Secomandi, Letizia Vallino, Riccardo Moia, Andrea Patriarca, Beatrice Garavaglia, Gianluca Gaidano, Ciro Isidoro

Summary: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous cancer characterized by dysregulated autophagy and apoptosis. The expression of BCL2 and BECN1 is inversely correlated in DLBCL patients, and cells with high BCL-2 expression are resistant to chemotherapy while cells with high BECLIN-1 expression are sensitive. Modulating BECLIN-1-dependent autophagy can affect the prognosis of DLBCL patients and potentially enhance the efficacy of chemotherapy.

CELLS (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.